Option Care Health (NASDAQ:OPCH) Updates Q4 2024 Earnings Guidance

Option Care Health (NASDAQ:OPCH) updated its fourth quarter 2024 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of 0.420-0.450 for the period, compared to the consensus earnings per share estimate of 0.330. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.

Option Care Health Price Performance

Shares of NASDAQ:OPCH opened at $27.72 on Tuesday. The business has a fifty day simple moving average of $23.20 and a 200-day simple moving average of $27.69. Option Care Health has a 52 week low of $21.39 and a 52 week high of $34.63. The company has a market cap of $4.72 billion, a P/E ratio of 23.29, a P/E/G ratio of 2.43 and a beta of 1.31. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77.

Analyst Ratings Changes

OPCH has been the topic of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and set a $30.00 price objective (down from $31.00) on shares of Option Care Health in a report on Friday. Jefferies Financial Group downgraded shares of Option Care Health from a “buy” rating to a “hold” rating and cut their price target for the stock from $38.00 to $26.00 in a research note on Thursday, October 31st. UBS Group started coverage on shares of Option Care Health in a research note on Thursday, December 5th. They set a “neutral” rating and a $26.00 price objective for the company. Bank of America raised Option Care Health from a “neutral” rating to a “buy” rating and increased their target price for the stock from $26.00 to $33.00 in a research report on Monday. Finally, The Goldman Sachs Group downgraded Option Care Health from a “buy” rating to a “neutral” rating and lowered their price target for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.71.

Insider Activity at Option Care Health

In other news, Director Harry M. Jansen Kraemer, Jr. acquired 43,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were bought at an average price of $22.54 per share, for a total transaction of $969,220.00. Following the completion of the purchase, the director now directly owns 326,334 shares of the company’s stock, valued at approximately $7,355,568.36. This trade represents a 15.18 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.64% of the stock is owned by insiders.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.